SMi’s 8th annual Imaging in Cancer Drug Development held on 14th &15th March 2012, London

Nov. 15, 2011 - PRLog -- Effective treatments for a wide verity of cancers are still very slow and costly to develop with many prospective drugs ending up in being scraped.

With the current economic climate businesses of all sizes are looking for new ways to develop drugs in a smarter manner with reduced production time and improved methods of predicting futility to prevent wasted time and money. Imaging is quickly seen as the way to do this pre-clinically, with in-vivo imaging being used to determine pharmacodynamics and pharmacokinetics of drug candidates and also to quantify tumour progression in order to measure drug efficacy.

Don’t miss out on this fantastic opportunity to network with experts in the field that includes:

•   Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
•   Yanping Luo, Group Leader Translational Imaging, Abbott
•   Peter Eggelton, Medical Director Oncology, Merck
•   Paul McSheehy, Director Oncology, Novartis
•   Anthony M Giamis, Head of Radiochemistry, Abbott
•   Christopher Foley, Imaging Manager, GlaxoSmithKline
•   Simon Walker-Samuel, Senior Research Associate, University College London
•   Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
•   Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK


There will also be an interactive pre-conference workshop held on the 13th March 2012 on.....
Can Molecular Imaging Reduce the Cost of Drug Development?
Lead by William Hallet, Imanova
8:30am - 12:30pm

For more information and to book your place visit http://www.smi-online.co.uk/cancer-imaging13.asp
Alternatively, contact Andrew Gibbons at Tel: +44 (0)20 7827 6156 or Email: agibbons@smi-online.co.uk